Publication Topic

Agarwal I, Frankenfeld C, Schernhammer E, Strohmaier S, Fleisch AF, Rich-Edwards J, Tobias DK. 2026. Rotating night shift work, gestational diabetes and risk of type 2 diabetes among US nurses. Occup Env Med; doi: 10.1136/oemed-2025-110594. Online ahead of print January 28. PMID: 41605642.

Frankenfeld CL, Movva N, Reichert H, Doepker C. Dietary intake and nutrient adequacy differ across GLP-1RA users based on length of GLP1-RA use. Poster 268, ObesityWeek 2025, Atlanta, GA, November 5, 2025.

Movva N, Girguis M, Bylsma L, Saleem N, Grasic K, Suh M, Pastula S, Frankenfeld C. 2025. Systematic literature review of glucagon-like peptide 1 (GLP-1) receptor agonist use among type 2 diabetes in the United States. PROSPERO 2025:CRD4202564618. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025646418.

Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ, Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2. PMID: 38170435.

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Torres KA. Diabetes specific ONS led to a blunted postprandial glucose response and a 26% reduction in peak blood glucose levels compared to a standard ONS. Presented at FNCE 2022 Food & Nutrition Conference & Expo, Orlando, FL, October 2022.

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Araujo Torres K. 2021. Effect of diabetes-specific oral nutritional supplements on postprandial glycemic response in adults with type 2 diabetes mellitus. Poster presented at ASPEN Nutrition Science & Practice Conference, March 2021.

Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A, Erickson D, Lee S. 2021. Fournier’s gangrene with dapagliflozin in a rural hospital: A case report. BMJ Case Rep 14(2):e237784; doi: 10.1136/bcr-2020-237784. PMID: 33526523.

Nordyke RJ, Appelbaum K, Berman MA.  2019. Estimating the impact of novel digital therapeutics in Type 2 diabetes and hypertension: Health economic analysis. J Med Internet Res 21(10):e15814; doi: 10.2196/15814. PMID: 31937249.

Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks NC, Cyr PL, Taylor S. 2019. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study. Clin Therapeut 41(2):303–313; doi: 10.1016/j.clinthera.2018.12.014; PMID: 30709610.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.